Adaptive Biotechnologies Corporation engages in immune-based discoveries and diagnostics by developing sequencing assays for clinical, research and drug development needs. It offers the immunoSEQ Platform which is comprised of the pairSEQ (TCR chain pairing) and MIRA(TCR antigen mapping) assays which profile T-cell receptor (TCR) and B-cell receptor genes for researchers to make discoveries in areas such as oncology, autoimmune disorders, infectious diseases and basic immunology and the clonoSEQ Assay which enables physicians to utilize a molecular, next-generation sequencing-based minimal/measurable residual disease (MRD) detection method for blood based tumors. The clonoSEQ Assay detects and quantifies DNA sequences found in malignant cells which can be tracked throughout treatment. This robust assay provides consistent, accurate measurement of disease burden which potentially allows physicians to visualize response to treatment over time. The company is also working with academic and strategic partners to create a personalized cancer therapeutics platform using its ability to identify key TCRs, extract them from the patients blood, amplify them and reintroduce them to the patient as a personalized TCR drug. In December 2017, the company announced it is utilizing its immune profiling expertise to identify early presentation of various diseases from a blood sample through a discovery partnership with Microsoft, which is providing the data management and AI expertise to the company’s discovery efforts. Microsoft also made a substantial investment in the company.